France

Poxel

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

USP Workshop 2021

Participation Not Confirmed

Update your events

Poxel Regains Imeglimin Rights From Metavant

Lead Product(s): Imeglimin Hydrochloride

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Metavant Sciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Terminated January 14, 2021

Details:

Metavant will return all rights to Imeglimin to Poxel, as well as all data, materials, and information, including FDA regulatory filings, related to the program. Metavant is not entitled to any payment from Poxel as part of the return of the program.

Creapharm

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

USP Workshop 2021

Participation Not Confirmed

Update your events

AzurRx BioPharma Enters into Packaging, Labeling and Distribution Agreement with Creapharm Clinical Supplies for MS1819 Trial Drug Product

Lead Product(s): MS1819,Porcine enzyme replacement therapy

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: AzurRx BioPharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 07, 2020

Details:

Creapharm will package, label, and distribute AzurRx’s MS1819 clinical trial drug product for both the upcoming Phase 2b OPTION 2 Monotherapy and the ongoing Phase 2 Combination Therapy Programs.

Delpharm Group

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

USP Workshop 2021

Participation Not Confirmed

Update your events

AzurRx Announces Manufacturing Agreement with Delpharm for MS1819 Clinical Drug Product

Lead Product(s): MS1819

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: AzurRx BioPharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement April 16, 2020

Details:

Under this agreement, Delpharm will manufacture AzurRx’s MS1819 cGMP batch that will be used in the Phase 2b OPTION 2 Clinical Trial for the treatment of EPI in patients with Cystic Fibrosis.